Breast cancer is the most prevalent tumor and a major cause of morbidity and mortality among women worldwide[@b1]. Over the past decades, there has been a significant increase in breast cancer incidence, with more than one million new cases each year[@b2]. Diagnosis of breast cancer at the early stage results in a high survival rate (∼98%), whereas diagnosis at the advanced stage results in a significantly lower survival rate (∼27%)[@b3]. Due to the lack of early detection methods for breast cancer, current therapies are necessary but not sufficient to improve the survival of women with breast cancer. Thus, identification of tumor markers for the early detection and therapeutic targeting of breast cancer is essential.

Although much progress has been made in understanding the biology of breast cancer, its etiology is still not very clear. Activation of oncogenes and inactivation of tumor suppressor genes (TSGs) synergistically contribute to the cancer progression. Early studies have demonstrated that genetic alterations, such as chromosomal translocations and point mutations, are responsible for TSG inactivation. Recently, accumulating evidence indicates that epigenetic alterations provide an alternative yet important mechanism for TSG silencing. Epigenetic modifications include DNA methylation and histone modifications, which cooperatively affect chromatin structure and genomic stability[@b4],[@b5]. Epigenetic modifications play important roles in the regulation of cell cycle, apoptosis, signal transduction, and tumorigenesis[@b6].

A series of TSGs silenced by promoter CpG methylation have been identified in breast cancer, indicating aberrant methylation of TSGs as a key factor in breast cancer pathogenesis. In addition, breast cancer usually progresses gradually from a less aggressive, hormone-dependent to a highly invasive, hormone-independent phenotype[@b7],[@b8], implying that silencing of hormone-mediated TSGs occurs in breast cancer progression. Frequent TSG methylation in breast cancer makes it a potentially useful marker for disease diagnosis. Here, we summarize some recent studies on epigenetic alterations in breast cancer and further discuss their biological and clinical implications.

Aberrant Promoter Methylation Silences Critical TSGs in Breast Carcinoma {#s2}
========================================================================

Although inactivating mutations of TSGs have been well documented in familial breast cancer, the incidence of mutations in sporadic breast cancer is rare. Yet, a large body of evidence has demonstrated that epigenetic aberration is a key player in silencing a variety of TSGs, which triggers breast tumor progression[@b9]. Identification of an epigenetic gene profile for breast cancer will thus be helpful to elucidate the molecular mechanisms underlying breast cancer pathogenesis.

As shown in [Table 1](#cjc-32-01-012-t01){ref-type="table"}, a series of promoter-methylated key TSGs involved in breast tumorigenesis have been reported, including genes for cell cycle regulation (*p16INK4a, p14ARF, p15, 14-3-3σ, cyclin D2, p57KIP2*) , DNA repair \[glutathione S-transferase pi 1 (*GSTP1*), O-6-methylguanine-DNA methyltransferase (*MGMT*), breast cancer 1 (*BRCA1*), human mutL homolog 1 (*hMLH1*)\], hormone and receptor-mediated cell signaling pathways \[estrogen receptor alpha (*ERα*), progesterone receptor (*PR*), retinoic acid receptor beta (*RARβ*), Ras association domain family member 1 (*RASSF1A*), spleen tyrosine kinase (*SYK*), TGFβ receptor II (*TGFβ RII*), high in normal 1 (*HIN1*), normal epithelial cell-specific 1 (*NES1*), suppressor of cytokine signaling 1 (*SOCS1*), secreted frizzled-related protein 1 (*SFRP1*), WNT inhibitory factor 1 (*WIF1*)\], apoptosis \[adenomatous polyposis coli (*APC*), death-associated protein kinase (*DAPK1*), hypermethylated in cancer 1 (*HIC1*), homeobox A5 (*HOXA5*), TWIST homolog of drosophila (*TWIST*), target of methylation-induced silencing (*TMS1*)\], cell adhesion and metastasis \[cadherin 1 (*CDH1*), cadherin 13 (*CDH13*), APC, tissue inhibitor of metalloproteinases 3 (*TIMP3*)\], angiogenesis \[maspin, thrombospondin 1 (*THBS1*)\], and other processes. These epigenetic changes may lead to chromosomal instability, accumulated mutations in critical cell signaling pathways, ultimately contributing to breast cancer progression. Our group has also identified a series of TSGs silenced or down-regulated by promoter CpG methylation in breast cancer, such as *WIF1*, phospholipase C delta 1 (*PLCD1*), CKLF-like MARVEL transmembrane domain containing 5 (*CMTM5*), CKLF-like MARVEL transmembrane domain containing 3 (*CMTM3*), opioid binding protein/cell adhesion molecule-like (*OPCML*), Ubiquitin carboxyl-terminal esterase L1 (*UCHL1*), deleted in liver cancer 1 (*DLC1*), interferon regulatory factor 8 (*IRF8*), and dapper homolog 1 (*DACT1*), that are involved in breast tumor cell cycle control, apoptosis, and metastasis[@b10]--[@b16].

Clinical Implications of Promoter Methylation in Breast Cancer {#s3}
==============================================================

Understanding the critical roles of promoter CpG methylation-mediated transcriptional repression/silencing in breast cancer led us to consider its potential clinical applications. Here, we further discuss the usage of DNA methylation markers for early cancer detection and prognosis prediction, as well as the application of demethylation drugs in breast cancer therapy.

Aberrant promoter methylation as a marker for early detection and prognosis in breast cancer {#s3a}
--------------------------------------------------------------------------------------------

Women diagnosed with early-stage breast cancer have a better prognosis and require less severe treatment regimens than those diagnosed with advanced stage diseases. With the development of magnetic resonance imaging (MRI) and digital mammography, the accuracy of breast cancer detection has distinctly increased. However, current screening methods lack sensitivity and specificity[@b17], and new methods with higher sensitivity, specificity, and lower invasiveness are urgently required. Using tumor markers thus provides a valuable alternative approach.

In recent years, many studies demonstrated that aberrant DNA methylation has strong potential to serve as a novel tumor marker for early diagnosis and progression evaluation. First, aberrant promoter methylation of a series of TSGs is a common feature of malignancy; compared to gene mutations and copy number alternations, it occurs more frequently as an early event in tumorigenesis. Importantly, different types of tumors present distinctive promoter methylation profiles, which can improve specificity and sensitivity for tumor detection. Second, aberrant promoter methylation patterns can be detected even when they are embedded in an excess amount of normal DNA molecules. Third, techniques required for the detection of methylation patterns, such as methylation-specific PCR (MSR), MethyLight, and quantitative multiplex methylation-specific PCR (QM-MSP), are relatively simple, rapid, non-radioactive, and sensitive.

A number of cancer-specific genes have been found to be frequently methylated in breast cancer. These epigenetic biomarkers show promise for distinguishing between malignant and benign disease or normal tissue[@b18]--[@b23]. Further, considering that no single methylated gene was detected in any breast cancer types, it is necessary to use cancer-specific methylation marker panels to screen breast cancer[@b24]. For example, a three-methylated-gene panel (*Cyclin D2, RARβ*, and *TWIST*) was successfully used to detect malignant breast cancer cells in ductal fluids[@b25]. A four-methylated-gene panel (*RASSF1A, TWIST, HIN1,* and *Cyclin D2*) with a high level of sensitivity and specificity was used to detect malignant breast tissues[@b26] as well. Compared to conventional ductal lavage cytology, a nine-methylated-gene panel (*RASSF1A, TWIST, HIN1, Cyclin D2, RARβ, APC, BRCA1, BRCA2,* and *p16*) was developed to double the sensitivity for breast cancer detection[@b27].

###### Summary of major tumor suppressor genes methylated in breast cancer

  Gene name       Chr location    Reported percentage of methylation in breast tumors   Reported percentage of methylation in breast cancer cell lines                                                Major functions                                                     Reference(s)
  -------------- --------------- ----------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------
  *ATM*             11q22-q23                             78%                                                         --                                                                     DNA repair, cell cycle regulator                                                [@b60]
  *ABCB1*            7q21.12                              --                                                          --                                                                           Multidrug resistance                                                  [@b61],[@b62]
  *APC*             5q21-q22                           36%--44%                                                      44%                                                                 Cell polarity and chromosome segregation                                        [@b63],[@b64]
  *BECN1*             17q21                               --                                                          --                                                                                 Autophage                                                           [@b65]
  *BIN1*              2q14                                18%                                                        100%                                                                                Apoptosis                                                           [@b66]
  *BMP6*            6p24-p23                              --                                                          --                                                                      Regulate TGFβ signaling pathway                                                [@b3]
  *BRCA1*           17q12-21                              51%                                                         --                                                   Cell cycle regulator, DNA repair, transcription regulation, apoptosis                         [@b67],[@b68]
  *CMTM5*            14q11.2                              --                                                         100%                                                                                Apoptosis                                                           [@b14]
  *CMTM3*            16q22.1                              18%                                                        44%                                                                                 Apoptosis                                                           [@b10]
  *C/EBPδ*        8p11.2-p11.1                            --                                                          --                                                Cellular proliferation, differentiation, metabolism, inflammatory response                           [@b69]
  *CDKN1C*           11p15.5                              --                                                         85%                                                                           Cell cycle regulator                                                      [@b70]
  *CST6*              11q13                            48%--60%                                                       --                                                                    Inhibit cystein proteases activity                                           [@b71],[@b72]
  *CDH3*             16q22.1                              --                                                          --                                                                        Calcium-dependent adhesion                                               [@b62],[@b73]
  *CDH13*           16q24.2-3                             33%                                                        35%                                                                 Cell adhesion, proliferation, metastasis                                            [@b74]
  *COX2*          1q25.2-q25.3                            35%                                                         --                                                                Cyclooxygenase-2; inflammation, mitogenesis                                          [@b75]
  *CDO1*             5q23.2                               --                                                          --                                                                                  Unknown                                                            [@b76]
  *CIDEA*            18p11.2                              53%                                                        86%                                                                      Caspase-independent cell death                                                 [@b77]
  *Cyclin D2*         12p13                               46%                                                         --                                                                           Cell cycle regulator                                                      [@b78]
  *DBC1*             9q32-33                              26                                                         33%                                                                                  Unknown                                                            [@b77]
  *DAPK*             9q34.1                               --                                                          --                                                                                 Apoptosis                                                           [@b79]
  *DKK1*             10q11.2                              19%                                                        27%                                                                           Wnt pathway inhibitor                                                     [@b80]
  *DKK3*             11p15.2                            61.30%                                                       71%                                                                           Wnt pathway inhibitor                                                     [@b81]
  *DLC1*              8p22                                36%                                                      22%--33%                                                                 Signal transduction, cell adhesion                                           [@b15],[@b82]
  *ER*               6q25.1                               49%                                                         --                                                                             Estrogen receptor                                                   [@b83]--[@b85]
  *E-cadherin*       16q22.1                              48%                                                      38%--55%                                                              Cell adhesion, proliferation, metastasis                                        [@b75],[@b86]
  *EMILIN2*          18p11.3                              44%                                                        56%                                                                    Extracellular matrix glycoproteins                                               [@b77]
  *EDN3*          20q13.2-q13.3                           70%                                                        83%                                                                                  Unknown                                                            [@b87]
  *EPHA5*            4q13.1                               64%                                                         --                                                                                  Unknown                                                            [@b88]
  *FLJ25161*         3p14.1                               57%                                                        75%                                                                                  Unknown                                                            [@b89]
  *FBXW7*            4q31.3                               50%                                                         --                                                                            Cell cycle control                                                       [@b90]
  *FBLN2*            3p25.1                               34%                                                        56%                                                                        Cell motility and invasion                                                   [@b77]
  *FOXC1*             6p25                                50%                                                         --                                                                           Embryonic development                                                     [@b62]
  *GADD45a*       1p31.2-p31.1                            67%                                                        67%                                                                       Growth arrest and DNA repair                                                  [@b91]
  *GSTP1*             11q13                               31%                                                        44%                                                                     Glutathione transferase activity                                                [@b92]
  *HER4*              2q34                                --                                                          --                                                                Tyrosine kinase-type cell surface receptor                                           [@b93]
  *HIC1*             17p13.3                              --                                                          --                                                                           Transcription Factor                                                      [@b94]
  *HIN1*            5q35-qter                             65%                                                         --                                                                  Cell communication,signal transduction                                         [@b95],[@b96]
  *HMLH1*            3p21.3                               14%                                                         --                                                                                DNA repair                                                           [@b62]
  *HOXD11*           2q31.1                               75%                                                        100%                                                                   Transcription factor, morphogenesis                                              [@b89]
  *HOXA5*           7p15-p14                              80%                                                         --                                                                         Transcription regulation                                                    [@b97]
  *IGF2*             11p15.5                              --                                                          --                                                                                  Unknown                                                            [@b98]
  *IRF8*             16q24.1                              36%                                                        66%                                                                           Transcription factor                                                      [@b16]
  *KV1.3*            1p13.3                             42.30%                                                        --                                                                                 Apoptosis                                                           [@b99]
  *OPCML*             11q25                               91%                                                        90%                                                                               Cell adhesion                                                         [@b11]
  *PCDH10*           4q28.3                               43%                                                        88%                                                                      Apoptosis, metastasis, invasion                                                [@b89]
  *P3H2*              3q28                                42%                                                        46%                                 A family of collagen prolyl hydroxylases required for proper collagen biosynthesis, folding, and assembly          [@b100]
  *P3H3*              12q13                               26%                                                        31%                                 A family of collagen prolyl hydroxylases required for proper collagen biosynthesis, folding, and assembly          [@b100]
  *PLCD1*          3p22-p21.3                             52%                                                        78%                                                      Phospholipase activity, cell cycle arrest, metastasis, invasion                                [@b13]
  *PCDHGB6*           5q31                                62%                                                        75%                                                                               Cell adhesion                                                         [@b89]
  *PGR*               11q22                               --                                                          --                                                                           Progesterone receptor                                                    [@b101]
  *PPP2R2B*           5q32                             56%--65%                                                       --                                                                     Cell growth and division control                                               [@b102]
  *P16/CDKN2A*        9p21                              0--67%                                                       33%                                                                             Cell cycle arrest                                                  [@b103]--[@b108]
  *PTEN*             10q23.3                           22%--76%                                                       --                                                          Cell cycle arrest, apoptosis, cell adhesion, migration                                 [@b62],[@b109]
  *RARB*              3p24                                --                                                          --                                                                        Tumor suppressive activity                                              [@b110],[@b111]
  *RRDM2*            1p36.21                              --                                                          --                                                                           Apoptosis, metastasis                                                    [@b112]
  *RASSF1A*          3p21.3                               62%                                                        100%                                                                Cell cycle control, apoptosis, DNA repair                                      [@b113]--[@b115]
  *SIM1*           6q16.3-q21                             75%                                                        100%                                                                                 Unknown                                                            [@b89]
  *SALL1*            16q12.1                              63%                                                        67%                                                                                  Unknown                                                            [@b77]
  *SFRP1*            8p11-12                           40%--75%                                                   30%--100%                                                                           Wnt antagonist                                                 [@b80],[@b116],[@b117]
  *SFRP2*            4q31.3                               77%                                                        100%                                                                             Wnt antagonist                                                         [@b80]
  *SFRP5*            10q24.1                           71%--73%                                                    90%--91%                                                                           Wnt antagonist                                                     [@b80],[@b118]
  *SOX17*            8q11.23                             80.6%                                                        --                                                                   Growth inhibition, cell cycle arrest                                             [@b119]
  *SRBC*              1p15                                60%                                                         --                                                                                  Unknown                                                           [@b120]
  *SYK*               9q22                                32%                                                        30%                                                                       Growth inhibition, metastasis                                                [@b121]
  *TIMP3*            22q12.3                              27%                                                        29%                                                                           Metastasis, invasion                                                     [@b122]
  *TWIST*            7p21.2                            5.6%--32%                                                      --                                                                       Transcription regulator, EMT                                              [@b95],[@b123]
  *TMS1*          16p11.2-12.1                            41%                                                        77%                                                                                 Apoptosis                                                          [@b124]
  *TGM2*              20q12                              44.4%                                                   5.7%--73.1%                                                                          Cell migration                                                        [@b125]
  *TRIP10*           19p13.3                              --                                                          --                                                                              Cell migration                                                        [@b126]
  *THRB*             3p24.2                              100%                                                        40%                                                                         Thyroid hormone receptor                                                   [@b127]
  *WIF1*             12q14.3                              67%                                                        80%                                                                          Wnt signaling inhibitor                                                    [@b12]
  *XT3*              3p21.3                               43%                                                        75%                                                                                  Unknown                                                            [@b89]
  *14-3-3δ*          2p25.1                            83%--96%                                                      50%                                                                       Cell cycle arrest, metastasis                                            [@b128],[@b129]

--, not available.

Cancer-specific methylation can also be extended to assess risk and predict prognosis for breast cancer. For example, frequently methylated *RASSF1A* and *APC*, as well as methylated *GSTP1* and *SFRP1*[@b28],[@b29], were associated with poor outcome[@b28],[@b29]. Recently, subtype-specific methylation markers were used to evaluate optional targeted treatments in breast cancer[@b30]. Using an array-based methylation assay, Holm *et al*.[@b31] uncovered a subtype- specific methylation pattern for distinguishing different breast tumor phenotypes, which will provide more detailed information for predicting breast cancer prognosis.

Additionally, blood-based detection of cancer-specific methylated DNA in breast cancer has shown potential for early detection and prognostic prediction[@b32]--[@b35].

Radpour *et al.*[@b3] found significant promoter methylation of seven genes \[*APC*, bridging integrator 1 (*BIN1*), bone morphogenetic protein 6 (*BMP6*), *BRCA1*, cystatin 6 (*CST6*), *P16*, and *TIMP3*\] in serum and tumor tissues from patients with breast cancer by using MALDI-TOF mass spectroscopy.

Together, these studies show that cancer specific methylation changes in tumor tissues, plasma, and other fluids can be used as tumor markers for risk assessment and early diagnosis of breast cancer. More effective and simplified approaches for detecting methylated genes are being developed to increase the sensitivity and specificity of early detection and prognosis of breast cancer[@b36]--[@b38].

Aberrant promoter methylation as therapeutic target for breast cancer {#s3b}
---------------------------------------------------------------------

Unlike genetic changes in cancers, gene silencing due to DNA methylation changes can be reversed by pharmacological demethylation. Thus, reactivating epigenetically silenced cancer genes and restoring their tumor suppression functions provide new insight for cancer therapy. Moreover, targeting epigenetic alterations also provides alternative ways for breast cancer preventative care, novel anticancer therapeutics, and drug investigation.

DNA methyltransferase (DNMTs) inhibitors, 5-aza-cytidine (5-Aza-CR) and 5-aza-2′-deoxycytidine (5-Aza-dC), are the first discovered epigenetic drugs. These compounds act by incorporating into DNA in place of the natural base, cytosine, during DNA replication, leading to covalent trapping of DNMTs[@b39]. This causes the depletion of active DNMTs and demethylation of genomic DNA. These reagents have already been approved by the US Food and Drug Administration (FDA) for treatment of a myelodysplastic syndrome (MDS), malignant mesothelioma, preleukemic disease, breast cancer, nasopharyngeal carcinoma (NPC) and other diseases[@b40]--[@b43]. Recently, Zebularine, a novel DNMT inhibitor with low toxicity and high selectivity for tumor cells, was reported to reactivate key genes silenced in breast cancer cell lines even at low doses[@b44]. In addition, other demethylation approaches, including DNMT inhibition via siRNA, ribozymes, and antisense oligonucleotides, have also been proposed but are still in their infancy. Some of these agents have been demonstrated to be promisingly effective in cell culture systems, animal models, and even clinical trials, whereas having little effect on normal cells[@b45]. These agents include MG98, an antisense oligonucleotide to DNA methyltransferase 1[@b46],[@b47], and RG108[@b48],[@b49], a novel small molecule that binds to the catalytic site of DNA methyltransferases.

The combination of histone deacetylases inhibitors (HDACIs), such as TSA and phenylbutyrate[@b50], with DNMT inhibitors is particularly valuable for cancer treatment. Furthermore, loss of estrogen receptor (ER) expression due to aberrant DNA methylation and histone modifications results in resistance to anti-estrogen therapy in breast cancer. Studies showed that combination of 5-azacytidine with TSA could induce re-expression of functional ER, thereby sensitizing ERα-negative breast cancer cells to tamoxifen therapy[@b15],[@b52]. Combined with HDACIs, trastuzumab (Herceptin^®^), a humanized monoclonal anti-HER2 antibody, produced a synergistic effect on cell growth repression and apoptosis induction in breast cancer cells[@b53],[@b54].

Furthermore, combinations of epigenetic drug treatments with conventional chemotherapeutic reagents or natural dietary ingredients could potentially work synergistically to increase therapeutic effects. A preclinical study has shown that 5-Aza-dC in combination with docetaxel, an anti-mitotic chemotherapeutic regent, could produce synergistic anti-cancer effects on breast cancer lines[@b55]. 5-Aza-dC combined with either amsacrine or idarubicin also showed promising efficacy. The green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), can cause the chromatin structural remodelling of ERα promoter by altering histone acetylation and methylation status, thereby resulting in ERα reactivation. Combined with TSA, EGCG reactivated multiple methylation-silenced TSGs by directly and indirectly inhibiting the enzymatic activities of DNMTs[@b56]. Dietary sulforaphane (SFN)[@b57], a histone deacetylase inhibitor, significantly inhibited the viability and proliferation of breast cancer cells but not normal cells *in vitro*.

Therefore, combined demethylation therapies may offer better therapeutic strategies for breast cancer. For example, clinical trials of trastuzumab combined with HDACI are in progress for locally advanced breast cancer[@b58], and a phase II breast cancer trial combining valproic acid (VPA) with FEC100 (5-fluorouracil, epirubicin, and cyclophosphamide) is ongoing[@b59].

Conclusions {#s4}
===========

In summary, substantial evidence demonstrates that epigenetic alterations, especially promoter CpG methylation of TSGs, play critical roles in breast tumorigenesis. Significant advances have been made for early detection biomarkers, risk assessment, prognostic prediction, and drug development in breast cancer. With the development of new epigenomic techniques and further investigations, a better perspective of the epigenetic profile of breast cancer will soon be revealed.
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